Bench to bedside: episode 1 - "walking the critical path"
BIA’s Science and Innovation Advisory Committee (SIAC) are delivering a series of webinars in 2019 entitled ‘Bench to Bedside’. The content has been proposed by industry and will explore the drug discovery process from discovery to delivery. The series will be concluded with a panel session at our UK Bioscience Forum on 17 October.
This webinar will discuss the critical path from discovery to market with an emphasis on strategies which can enhance potential for success.
Dr Penny Ward
Penny has more than 20 years of experience in clinical development and medical affairs. Her work has contributed to the approval of multiple therapies for the treatment of infectious diseases, osteoporosis and autoimmune disorders in the US, EU and Japan. She was the Global Clinical Development Leader for Tamiflu, which was approved in an industry-leading rapid timeframe and additionally contributed to the development of antiviral therapies for HIV (Fuzeon, Invirase, Viracept, Aptivus and Rescriptor), CMV (Valcyte) and Hepatitis (Pegysys). During her extensive career, Penny has held senior management roles in Pharmacia and Upjohn, Roche, Glaxo SmithKline and UCB, and has served as Chief Medical Officer for several start up companies including Blue Earth Diagnostics, Karus Therapeutics, Topivert and Novimmune. Penny qualified in medicine from University College Hospital London and is a Visiting Senior Lecturer in Pharmaceutical Medicine at Kings College, London.
Next episodes 2019:
Episode 2 Harnessing ‘Omics - 12 July
Episode 3 What Translational Science Can and Cannot Do - 6 September
Episode 4 From Biomarker to Surrogate - 11 October
Concluding session - UK Bioscience Forum, 17 October, London